Clinical Trial Update: Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC [Phase 2]

View source ↗

Summary

A prospective multicenter Phase 2 single-arm trial evaluating AK112 plus nab-paclitaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AK112
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Shuangyue Liu | Conditions: Breast Cancer - Female | Phase 2 | Status: NOT_YET_RECRUITING